A Systematic Review: Outcomes in Adult Recurrent Respiratory Papillomatosis Treated with Intralesional Cidofovir or Bevacizumab

  title={A Systematic Review: Outcomes in Adult Recurrent Respiratory Papillomatosis Treated with Intralesional Cidofovir or Bevacizumab},
  author={Sarah M. Drejet and Stacey Halum and Matthew T. Brigger and Elaine N. Skopelja and Noah P. Parker},
  journal={Otolaryngology–Head and Neck Surgery},
  pages={435 - 441}
Objectives (1) To systematically identify studies evaluating the use of intralesional cidofovir or bevacizumab as an adjunct in adult recurrent respiratory papillomatosis, determine disease severity and functional outcomes, and assess study quality. (2) To compare outcomes between the 2 adjuncts. Data Sources Ovid Medline, EMBASE, Scopus, and Clinical-Trials.gov. Review Methods Data sources were systematically searched. A priori inclusion and exclusion criteria were instituted. Quality was… 

Figures and Tables from this paper

Eficacia del cidofovir intralesional en el tratamiento de papilomatosis respiratoria recurrente juvenil: una revisión sistemática
background: Juvenile recurrent respiratory papillomatosis is a chronic disease of viral etiology that usually requires repeated surgical interventions in order to avoid respiratory obstruction an
Recurrent Respiratory Papillomatosis Office versus Operating Room: Systematic Review and Meta-Analysis
The overall data indicate no differences aside from cost and imply that office procedures may be more cost-effective than OR procedures, however, the heterogeneous data limits any strong comparison of outcomes between office and OR-based treatment of laryngeal papillomas.
Systemic and Intralesional Bevacizumab in Juvenile Onset Recurrent Respiratory Papillomatosis: A Report of Two Cases
The patients who received bevacizumab, either systemically or intralesionally, show decreased need for surgeries mostly and even remission in a few, and this is a report of two cases of juvenile onset RRP with use of systemic bevacszumab infusion in a child and intralsional injection in an adult.
Systemic Bevacizumab (Avastin) for Juvenile‐Onset Recurrent Respiratory Papillomatosis: A Systematic Review
Systemic bevacizumab has shown initial success for severe JORRP and usage, effectiveness, and safety of this treatment was assessed.
Recurrent Respiratory Papillomatosis: Review and Treatment Update
Recurrent Respiratory Papillomatosis: Review and Treatment Update is a review and treatment update.
Methodological Quality of Systematic Reviews and Meta-analyses Published in High-Impact Otolaryngology Journals
Intervention-focused systematic reviews and meta-analyses published in high-impact otolaryngology journals have important methodological limitations that diminish confidence in the results of these reviews.
Tracheal tumors.
Although studies are still trying to find the best surgical techniques as well as the role for chemotherapy and radiation, most recent studies are addressing tracheal reconstruction and transplantation as the new horizon for management.


Adult intralesional cidofovir therapy for laryngeal papilloma: a 10-year perspective.
Intralesional cidofovir injections have been shown to be an effective therapy for adult laryngeal papilloma and should be considered in those patients who experience disease relapse.
Cidofovir Efficacy in Recurrent Respiratory Papillomatosis: A Randomized, Double-Blind, Placebo-Controlled Study
A significant improvement was found in the Derkay Severity Score 12 months after the baseline assessment in patients treated with cidofovir, however, this effect was also seen in the placebo group, and the trial was unable to provide proof of efficacy of cid ofovir in the treatment of RRP.
Efficacy of cidofovir injection for the treatment of recurrent respiratory papillomatosis.
Natural History of Adult-Onset Laryngeal Papillomatosis following Multiple Cidofovir Injections
The effectiveness of intralesional cidofovir therapy in adult-onset recurrent respiratory papillomatosis was impressive and complete remission was stable on intermediate or long-term follow-up.
Effectiveness of cidofovir intralesional treatment in recurrent respiratory papillomatosis
Intralesional cidofovir injection has been shown to be an effective and safe therapy for laryngeal papillomatosis and should be considered in those patients who experienced disease relapse.
Treatment of recurrent respiratory papillomatosis with microsurgery in combination with intralesional cidofovir—a prospective study
  • F. Dikkers
  • Medicine
    European Archives of Oto-Rhino-Laryngology and Head & Neck
  • 2005
The goal of this study is to assess the benefit of the intralesional injection of cidofovir as an adjunct to microsurgical excision in treatment of laryngeal papillomatosis.
Recurrent respiratory papillomatosis by HPV: review of the literature and update on the use of cidofovir
  • M. Fusconi, M. Grasso, M. de Vincentiis
  • Medicine, Biology
    Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale
  • 2014
Combination of surgical removal and injection of cidofovir is associated with good response in recurrent respiratory papillomatosis, and the hypothesis that cid ofovir may promote evolution towards dysplasia is disproved.
Experience of 11 years use of cidofovir in recurrent respiratory papillomatosis
Results show promising long-term effects of adjuvant use of cid ofovir in treatment of RRP with cidofovir during the last 11 years and did not observe any relevant side effects.
A Staging System for Assessing Severity of Disease and Response to Therapy in Recurrent Respiratory Papillomatosis
Recurrent respiratory papillomatosis is an orphan disease with an incidence in the United States estimated at between 1500 and 2500 new cases per year, and is considered the most common benign neoplasm of the larynx.
Use of cidofovir in HPV patients with recurrent respiratory papillomatosis
Results show promising long-term effects of adjuvant use of cidofovir, without any relevant side effects, in recurrent respiratory papillomatosis.